

Listing of Claims

This listing of claims will replace all prior versions and listing of claims in the application.

1. (Previously Amended) A method of treating osteoarthritis consisting of administering, to a subject suffering from osteoarthritis, a pharmaceutical composition consisting essentially of at least one pharmaceutically acceptable carrier and a therapeutically effective amount of an anti-IL-6 antibody.
2. (Original) The method of claim 1, wherein said pharmaceutical composition is administered interarticularly or intravenously.
3. (Withdrawn) The method of claim 1, wherein said agent is a monoclonal IL-6 receptor antibody.
4. (Withdrawn) The method of claim 3, wherein said IL-6 receptor antibody is an anti-human IL-6 receptor antibody.
5. (Withdrawn) The method of claim 3, wherein said IL-6 receptor antibody is tocilizumab.
6. (Original) The method of claim 1, wherein said agent is a monoclonal IL-6 antibody.
7. (Original) The method of claim 6, wherein said IL-6 antibody is an anti-human IL-6 antibody.
8. (Original) The method of claim 6, wherein said IL-6 antibody is CNTO 328.
9. (Original) The method of claim 6, wherein said pharmaceutical composition is administered interarticularly.
10. (Original) The method of claim 6, wherein said pharmaceutical composition is administered intravenously.

11. (Previously Amended) A method of treating osteoarthritis consisting of administering, to a subject suffering from osteoarthritis, a pharmaceutical composition consisting essentially of at least one pharmaceutically acceptable carrier, a therapeutically effective amount of an anti-IL-6 antibody, and one or more agents selected from the group consisting of: 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid calcium salt, non-steroidal anti-inflammatory agents, piroxicam, diclofenac, naproxen, flurbiprofen, fenoprofen, ketoprofen, ibuprofen, mefenamic acid, indomethacin, sulindac, apazone, phenylbutazone, aspirin, hyalgan, and synvisc.
12. (Previously Amended) A method of treating osteoarthritis consisting of administering, to a subject suffering from osteoarthritis, a pharmaceutical composition consisting essentially of at least one pharmaceutically acceptable carrier, a therapeutically effective amount of an anti-IL-6 antibody, and one or more agents selected from the group consisting of: parecoxib, celecoxib, valdecoxib, and etoricoxib.
13. (Cancelled) The method of use of one or more agents selected from the group consisting of: an anti-IL-6 antibody and an anti-IL-6 receptor antibody, in the manufacture of a medicament for the treatment of osteoarthritis in mammals.